QR CODE |
POSTER ID |
POSTER |
001 |
P4.4. |
LONG-TERM SAFETY AND EFFICACY OF MYOBLOC® (RIMABOTULINUMTOXINB) IN THE TREATMENT OF ADULT SIALORRHEA |
002 |
P4.5. |
MYOBLOC® (RIMABOTULINUMTOXINB) IN THE TREATMENT OF ADULT SIALORRHEA |
003 |
P9.24. |
THE MOLLII-SUIT®—A NOVEL METHOD USING RECIPROCAL INHIBITION IN CHILDREN WITH CEREBRAL PALSY, GROSS MOTOR FUNCTION CLASSIFICATION SYSTEM IV-V: A 6-MONTH PROSPECTIVE STUDY |
004 |
P3.69. |
CRYONEUROTOMY AS A NOVEL ADJUNCT TO BOTULINUM TOXIN TREATMENT FOR THE SPASTIC ELBOW: A CASE STUDY |
005 |
P3.27. |
5-YEAR FOLLOW-UP AFTER FIRST BOTULINUM TOXIN TYPE A INJECTION IN REAL-LIFE POSTSTROKE SPASTICITY: A SINGLE-CENTER EXPERIENCE IN BARCELONA |
006 |
P7.4. |
CASE SERIES: TREATMENT OF PHANTOM PAIN USING BOTULINUM TOXIN |
007 |
P9.1. |
INCOBOTULINUMTOXINA (XEOMIN®) IN DELAYED FACIAL NERVE PALSY DEVELOPING AFTER VESTIBULAR SCHWANNOMA RESECTION |
008 |
P9.2. |
TREATMENT OF SYNKINESIS AND MASTICATORY MUSCLE HYPERTROPHY WITH INCOBOTULINUMTOXINA (XEOMIN®) IN PATIENTS WITH FACIAL NERVE INJURY AFTER NEUROSURGICAL INTERVENTION |
009 |
P3.41. |
THE MAXIMUM TOTAL DOSAGE OF ABOBOTULINUMTOXINA FOR MULTILEVEL INJECTIONS IN PATIENTS WITH CEREBRAL PALSY, GMFCS LEVELS IV-V |
010 |
P3.44. |
BOTULINUM TOXIN IS PRESCRIBED FOR SPASTICITY OR SPASTIC DYSTONIA? |
011 |
P7.6. |
EFFECTS OF INTRAMUSCULAR BOTULINUM TOXIN INJECTIONS ON HEMIPLEGIC SHOULDER PAIN |
012 |
P3.31. |
APPROPRIATE DOSAGE (FROM 100 TO 1000 U) OF INCOBOTULINUMTOXINA IN SPASTICITY |
013 |
P4.3. |
LONG-TERM EFFICACY OF INCOBOTULINUMTOXINA IN THE MANAGEMENT OF SIALORRHEA IN PARKINSON’S DISEASE |
014 |
P9.19. |
SERVICE EVALUATION OF A PHYSIOTHERAPIST-LED BOTULINUM TOXIN (PLBT) INJECTION THERAPY CLINIC |
015 |
P3.15. |
A 10-YEAR RETROSPECTIVE REVIEW OF LOWER LIMB BOTULINUM TOXIN INJECTION FOR SPASTICITY |
016 |
P3.12. |
TREATMENT OF SPASTICITY DUE TO THROMBOTIC BRAIN INJURY WITH INCOBOTULINUMTOXINA: A CASE REPORT |
017 |
P1.25. |
DUPLICATION OF NEURONAL BINDING DOMAINS DERIVED FROM CLOSTRIDIAL NEUROTOXINS GREATLY ENHANCES INTRANEURONAL DELIVERY OF THERAPEUTICS |
018 |
P3.4. |
INFLUENCE OF COMBINED USE OF BOTULINUM THERAPY AND ROBOTIC KINESIOTHERAPY ON INDICATORS OF GENERAL MOTOR FUNCTION IN CHILDREN WITH CEREBRAL PALSY |
019 |
P7.12. |
DOES ONABOTULINUMTOXINA HAVE ANY CENTRAL EFFECTS IN CHRONIC MIGRAINE? |
020 |
P2.7. |
ABOBOTULINUMTOXINA USING 2 mL DILUTION MAINTAINS DURABLE FUNCTIONAL IMPROVEMENTS ACROSS MULTIPLE TREATMENT CYCLES |
021 |
P2.20. |
BOTULINUM TOXIN INJECTIONS ARE ABLE TO IMPROVE QUALITY OF LIFE AND DAILY LIVING ACTIVITIES IN PATIENTS WITH UPPER LIMB TREMOR |
022 |
P9.12. |
SONOGRAPHY-GUIDED INJECTION IN THE NECK MUSCLES: IS IT REALLY THE GOLD STANDARD? |
023 |
P2.21. |
CLINICAL GUIDANCE OF BOTULINUM TOXIN INJECTIONS IN CERVICAL DYSTONIA: HOW ACCURATE IS NEEDLE PLACEMENT? |
024 |
P1.39. |
THE TRANSCRIPTOME OF CELL CULTURES DERIVED FROM MUSCLE BIOPSIES OF CONTROLS AND SPASTIC PATIENTS IS AFFECTED BY BOTULINUM TOXIN TYPE A |
025 |
P6.13. |
CLINICAL ASPECTS OF USING AN UPPER FACE MAPPING SYSTEM FOR ADMINISTRATION OF BOTOX® |
026 |
P2.4. |
MANAGEMENT ALGORITHM FOR BoNT INJECTIONS WITH ELECTROMYOGRAPHY AND ULTRASOUND GUIDANCE IN CERVICAL DYSTONIA |
027 |
P5.1. |
PILOT STUDY OF BOTULINUM TOXIN TYPE A UTERINE MUSCLE INJECTION IN THE TREATMENT OF ACUTE DYSMENORRHEA, UTERINE PAIN, AND DEEP DYSPAREUNIA |
028 |
P3.6. |
TREATMENT DIARY: A TOOL TO OPTIMIZE TREATMENT WITH BOTULINUM TOXIN |
029 |
P3.26. |
EFFECT OF CHEMODENERVATION AND SERIAL CASTING ON GAIT PARAMETERS IN ACQUIRED BRAIN INJURY PATIENTS WITH UPPER EXTREMITY SPASTICITY |
030 |
P7.10. |
WHAT BOTULINUM TOXIN TYPE A TELLS US ABOUT THE ROLE OF MYOFASCIAL SYNDROMES IN THE CLINICAL COURSE OF MIGRAINE |
031 |
P3.18. |
VIDEO AND TEMPORAL SPATIAL PARAMETER ASSESSMENT OF GAIT PRE-/POST- ABOBOTULINUMTOXINA TREATMENT |
032 |
P1.5. |
THE BINACLE (BINDING AND CLEAVAGE) ASSAY FOR IN VITRO DETERMINATION OF BOTULINUM NEUROTOXIN ACTIVITY |
033 |
P7.8. |
IMPROVEMENT OF REFRACTORY PELVIC MYOFASCIAL PAIN WITH INCOBOTULINUMTOXINA |
034 |
P3.59. |
ASSESSMENT OF THE EFFECT OF INCOBOTULINUMTOXINA ON MUSCLE TONE IN CHILDREN WITH SPASTIC DIPLEGIC OR TETRAPLEGIC CEREBRAL PALSY |
035 |
P9.15. |
ELECTROPHYSIOLOGIC ABNORMALITIES IN IATROGENIC BOTULISM: 2 CASE REPORTS |
036 |
P3.14. |
SWITCHING FROM ONABOTULINUMTOXINA TO ABOBOTULINUMTOXINA IN CHILDREN WITH CEREBRAL PALSY TREATED FOR SPASTICITY: A RETROSPECTIVE SAFETY EVALUATION |
037 |
P3.13. |
LONG-TERM IMPROVEMENT ON GMFCS LEVEL OF PATIENTS WITH CEREBRAL PALSY TREATED BY AN INTEGRATED APPROACH OF REPEATED BOTULINUM TOXIN TYPE A INJECTIONS |
038 |
P9.4. |
BOTULINUM TOXIN IN THE TREATMENT OF RESISTANT DEPRESSIVE DISORDER: COMPARISON OF 2 FACIAL INJECTION SITES |
039 |
P6.1. |
CONVERSION FROM ONABOTULINUMTOXINA TO INCOBOTULINUMTOXINA FOR AESTHETIC TREATMENTS: A CANADIAN MULTICENTER, REAL-WORLD, RETROSPECTIVE STUDY |
040 |
P9.17. |
FUNCTIONAL POPLITEAL ARTERY ENTRAPMENT SYNDROME (FPAES) TREATMENT WITH INCOBOTULINUMTOXINA: 3 SUCCESSFUL CLINICAL CASES |
041 |
P3.58. |
ROLE OF EARLY BOTULINUM TOXIN TYPE A INJECTION IN THE TREATMENT OF PATIENTS WITH POSTSTROKE SPASTICITY: PRELIMINARY RESULTS OF AN OBSERVATIONAL STUDY |
042 |
P3.7. |
FOCAL SPASTICITY IN MULTIPLE SCLEROSIS: TREATMENT-GOAL ATTAINMENT EVALUATION AFTER BOTULINUM TOXIN TYPE A THERAPY AND PHYSICAL REHABILITATION |
043 |
P4.2. |
BOTULINUM TOXIN TREATMENT OF SIALORRHEA IN CHILDREN |
044 |
P6.2. |
SAFETY AND EFFICACY OF ONABOTULINUMTOXINA FOR TREATMENT OF MASSETER MUSCLE HYPERTROPHY: RESULTS FROM A PHASE 2 DOSE-ESCALATION STUDY |
045 |
P5.4. |
METHODOLOGICAL APPROACHES TO USING BOTULINUM TOXIN FOR VAGINISMUS AND PELVIC PAIN IN WOMEN |
046 |
P2.16. |
DELAYED AND PROLONGED ARM WEAKNESS AND ATROPHY FOLLOWING BOTULINUM TOXIN INJECTION FOR MUSICIAN’S CRAMP |
047 |
P3.28. |
BREAKING A DOGMA: HIGH DOSES OF INCOBOTULINUMTOXINA TO TREAT SEVERE LIMB SPASTICITY WITH COMPLEX CLINICAL PATTERNS: A RETROSPECTIVE, MULTICENTER STUDY |
048 |
P6.4. |
SAFETY OF INCOBOTULINUMTOXINA IN THE TREATMENT OF FACIAL LINES: RESULTS FROM A POOLED ANALYSIS OF RANDOMIZED, PROSPECTIVE, CONTROLLED CLINICAL STUDIES |
049 |
P1.19 |
COMPARISON OF XEOMIN® TO BOTULINUM NEUROTOXIN TYPE A FORMULATIONS IN ASIA |
050 |
P9.9. |
INCOBOTULINUMTOXINA: A UNIQUE AND PURE FORMULATION OF BOTULINUM NEUROTOXIN TYPE A FOR USE IN AESTHETIC AND THERAPEUTIC MEDICINE |
051 |
P6.8. |
EFFICACY OF INCOBOTULINUMTOXINA FOR TREATMENT OF GLABELLAR FROWN LINES IN MALE SUBJECTS: POST HOC ANALYSES FROM RANDOMIZED, DOUBLE-BLIND PIVOTAL STUDIES |
052 |
P1.23. |
DECREASE IN THERAPEUTIC EFFECT AMONG BOTULINUM NEUROTOXIN TYPE A AGENTS: ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM DATABASE |
053 |
P6.10. |
EFFICACY AND SAFETY OF INCOBOTULINUMTOXINA IN THE TREATMENT OF UPPER FACIAL LINES: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY |
054 |
P6.11. |
SAFETY, TOLERABILITY, AND EFFICACY OF REPEAT-DOSE INJECTIONS OF INCOBOTULINUMTOXINA IN THE TREATMENT OF UPPER FACIAL LINES: RESULTS FROM A PROSPECTIVE, OPEN-LABEL, PHASE 3 STUDY |
055 |
P6.16. |
SAFETY AND EFFICACY OF INCOBOTULINUMTOXINA FOR THE TREATMENT OF UPPER FACIAL LINES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY WITH OPEN-LABEL EXTENSION |
056 |
P6.12. |
ESCALATING DOSES OF INCOBOTULINUMTOXINA FOR EXTENDED TREATMENT OF GLABELLAR FROWN LINES: SAFETY AND EFFICACY RESULTS FROM A RANDOMIZED, DOUBLE-BLIND STUDY |
057 |
P2.13. |
EVALUATION OF THE EFFECTIVENESS OF BOTULINUM TOXIN TYPE A IN THE COMPLEX APPROACH TO TREATMENT IN PATIENTS WITH CERVICAL DYSTONIA |
058 |
P2.2. |
ANTEROCOLLIS POSTURE AND DEEP CERVICAL MUSCLE INJECTIONS WITH BoNT |
059 |
P3.17. |
INDIVIDUALIZED ONABOTULINUMTOXINA TREATMENT FOR LOWER LIMB SPASTICITY RESULTED IN HIGH PATIENT AND CLINICIAN SATISFACTION IN THE ASPIRE STUDY |
060 |
P3.20. |
EFFICACY AND SAFETY OF ONABOTULINUMTOXINA FOR TREATMENT OF PEDIATRIC UPPER LIMB SPASTICITY: PRIMARY RESULTS |
061 |
P3.23. |
INDIVIDUALIZED ONABOTULINUMTOXINA TREATMENT FOR UPPER LIMB SPASTICITY RESULTED IN HIGH PATIENT AND CLINICIAN SATISFACTION IN THE ASPIRE STUDY |
062 |
P3.24. |
ONABOTULINUMTOXINA TREATMENT UTILIZATION VARIES BY ETIOLOGY OF SPASTICITY, WHILE MAINTAINING HIGH PATIENT AND CLINICIAN SATISFACTION: RESULTS FROM THE ASPIRE STUDY |
063 |
P3.37. |
EFFICACY AND SAFETY OF ONABOTULINUMTOXINA FOR THE TREATMENT OF PEDIATRIC LOWER LIMB SPASTICITY: PRIMARY RESULTS |
064 |
P5.5. |
EARLY AND CONSISTENT IMPROVEMENTS IN URINARY SYMPTOMS AND QUALITY OF LIFE WITH ONABOTULINUMTOXINA IN OVERACTIVE BLADDER PATIENTS WITH URINARY INCONTINENCE IN A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 4 TRIAL |
065 |
P2.19. |
CAMPTOCORMIA TREATMENT WITH INCOBOTULINUMTOXINA (XEOMIN®) IN PATIENTS WITH PARKINSON’S DISEASE |
066 |
P3.39. |
DETERMINATION OF THE INTRAMUSCULAR MOTOR ENDPOINT FOR EFFECTIVE ADMINISTRATION OF BOTULINUM TOXIN IN THE TREATMENT OF SPASTICITY |
067 |
P9.21. |
HYPERHIDROSIS: QUALITY OF LIFE AND TREATMENT WITH BOTULINUM TOXIN TYPES A AND B |
068 |
P4.9. |
INCOBOTULINUMTOXINA INJECTIONS INTO THE SALIVARY GLANDS FOR SIALORRHEA: LUIGI SACCO HOSPITAL EXPERIENCE IN MILAN |
069 |
P9.16. |
CLINICAL PRESENTATION OF AN OUTBREAK OF FOODBORNE BOTULISM IN SOUTHERN DENMARK |
070 |
P9.20. |
TREATMENT OF SELF-BITING BEHAVIOUR IN LESCH-NYHAN SYNDROME: USE OF BOTULINUM TOXIN |